|
Feb 27
|
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
|
|
Feb 27
|
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
|
|
Jan 10
|
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
|
|
Jan 5
|
Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares
|
|
Dec 22
|
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
|
|
Dec 19
|
Zai Lab Announces Participation in January Investor Conference
|
|
Dec 13
|
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
|
|
Dec 13
|
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
|
|
Dec 7
|
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
|
|
Aug 10
|
Penn downgraded, Roblox upgraded: Wall Street's top analyst calls
|
|
Aug 7
|
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
|